Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb’s and Pfizer’s Eliquis (Apixaban) drug has failed to prevent Venous Thromboembolism (VTE) in seriously ill medical patients during Phase 3 Apixaban Dosing to Optimize Protection from Thrombosis (ADOPT) study.
Subscribe to our email newsletter
During the study, Apixaban had failed to meet the primary efficacy outcome of superiority to Enoxaparin drug for the endpoint of VTE and VTE-related death.
Brigham and Women’s Hospital, senior cardiologist Samuel Z. Goldhaber said solving the problem of VTE post-hospitalization remains a critical unmet need in preventing medically ill patients from developing deep vein thrombosis and pulmonary embolism.
"ADOPT provides important insights for clinical trialists designing studies of extended duration VTE prophylaxis among medically ill hospitalized patients," Goldhaber added.
The new oral direct factor Xa inhibitor, Eliquis, is used to prevent VTE in European adult patients who have undergone elective total hip or knee replacement surgery.